{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:05:48Z","timestamp":1789607148738,"version":"build-2803163510"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":80,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2024A1515013208"],"award-info":[{"award-number":["2024A1515013208"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"name":"General Planned Project of Guangzhou Science and Technology","award":["2023A04J2254"],"award-info":[{"award-number":["2023A04J2254"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"DOI":"10.1007\/s00018-026-06315-w","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T05:04:59Z","timestamp":1782709499000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["TROP2 promotes bone metastasis of colorectal cancer through interaction with the fibronectin-integrin axis"],"prefix":"10.1007","volume":"83","author":[{"given":"Le-Xin","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Lin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Hong","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Ping","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Mei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Liang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Rong","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1343-0902","authenticated-orcid":false,"given":"Yi-Fan","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-Shan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"issue":"3","key":"6315_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"6315_CR2","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1067\/j.cpsurg.2018.08.004","volume":"55","author":"CL Stewart","year":"2018","unstructured":"Stewart CL et al (2018) Cytoreduction for colorectal metastases: liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure? Curr Probl Surg 55(9):330\u2013379","journal-title":"Curr Probl Surg"},{"issue":"12","key":"6315_CR3","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1002\/jbmr.3618","volume":"33","author":"J Fornetti","year":"2018","unstructured":"Fornetti J, Welm AL, Stewart SA (2018) Understanding the Bone in Cancer Metastasis. J Bone Min Res 33(12):2099\u20132113","journal-title":"J Bone Min Res"},{"issue":"1","key":"6315_CR4","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s10585-020-10069-5","volume":"38","author":"X Li","year":"2021","unstructured":"Li X et al (2021) Survival outcome and prognostic factors for colorectal cancer with synchronous bone metastasis: a population-based study. Clin Exp Metastasis 38(1):89\u201395","journal-title":"Clin Exp Metastasis"},{"key":"6315_CR5","doi-asserted-by":"crossref","unstructured":"Lenart S et al (2020) Trop2: Jack of All Trades, Master of None. Cancers (Basel) 12(11):3328","DOI":"10.3390\/cancers12113328"},{"issue":"4","key":"6315_CR6","doi-asserted-by":"publisher","first-page":"188902","DOI":"10.1016\/j.bbcan.2023.188902","volume":"1878","author":"S Qiu","year":"2023","unstructured":"Qiu S et al (2023) Targeting Trop-2 in cancer: Recent research progress and clinical application. Biochim Biophys Acta Rev Cancer 1878(4):188902","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"6315_CR7","doi-asserted-by":"publisher","first-page":"108296","DOI":"10.1016\/j.pharmthera.2022.108296","volume":"239","author":"X Liu","year":"2022","unstructured":"Liu X et al (2022) Advances in Trop2-targeted therapy: Novel agents and opportunities beyond breast cancer. Pharmacol Ther 239:108296","journal-title":"Pharmacol Ther"},{"key":"6315_CR8","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jare.2023.05.012","volume":"58","author":"W Tang","year":"2024","unstructured":"Tang W et al (2024) Targeting Trop2 by Bruceine D suppresses breast cancer metastasis by blocking Trop2\/beta-catenin positive feedback loop. J Adv Res 58:193\u2013210","journal-title":"J Adv Res"},{"key":"6315_CR9","first-page":"100763","volume":"37","author":"L Holladay","year":"2023","unstructured":"Holladay L et al (2023) Current and potential treatment of colorectal cancer metastasis to bone. Cancer Treat Res Commun 37:100763","journal-title":"Cancer Treat Res Commun"},{"key":"6315_CR10","doi-asserted-by":"crossref","unstructured":"Zi-Chen G et al (2020) Colorectal cancer cells promote osteoclastogenesis and bone destruction through regulating EGF\/ERK\/CCL3 pathway. Biosci Rep 40(6):BSR20201175","DOI":"10.1042\/BSR20201175"},{"key":"6315_CR11","doi-asserted-by":"publisher","first-page":"1274474","DOI":"10.3389\/fimmu.2024.1274474","volume":"15","author":"F Riaz","year":"2024","unstructured":"Riaz F, Zhang J, Pan F (2024) Forces at play: exploring factors affecting the cancer metastasis. Front Immunol 15:1274474","journal-title":"Front Immunol"},{"key":"6315_CR12","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/bonekey.2015.32","volume":"4","author":"N Baschuk","year":"2015","unstructured":"Baschuk N, Rautela J, Parker BS (2015) Bone specific immunity and its impact on metastasis. Bonekey Rep 4:665","journal-title":"Bonekey Rep"},{"issue":"3","key":"6315_CR13","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1053\/j.seminoncol.2019.08.002","volume":"46","author":"JW Rick","year":"2019","unstructured":"Rick JW et al (2019) Fibronectin in malignancy: Cancer-specific alterations, protumoral effects, and therapeutic implications. Semin Oncol 46(3):284\u2013290","journal-title":"Semin Oncol"},{"key":"6315_CR14","doi-asserted-by":"crossref","unstructured":"Lin TC et al (2019) Fibronectin in Cancer: Friend or Foe. Cells 9(1):27","DOI":"10.3390\/cells9010027"},{"issue":"1","key":"6315_CR15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40364-024-00580-2","volume":"12","author":"A Hazrati","year":"2024","unstructured":"Hazrati A et al (2024) Therapeutic and immunomodulatory potentials of mesenchymal stromal\/stem cells and immune checkpoints related molecules. Biomark Res 12(1):35","journal-title":"Biomark Res"},{"issue":"3","key":"6315_CR16","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1007\/s13577-020-00369-z","volume":"33","author":"Q Wang","year":"2020","unstructured":"Wang Q et al (2020) Interplay between mesenchymal stem cell and tumor and potential application. Hum Cell 33(3):444\u2013458","journal-title":"Hum Cell"},{"issue":"7586","key":"6315_CR17","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature17038","volume":"529","author":"J Massague","year":"2016","unstructured":"Massague J, Obenauf AC (2016) Metastatic colonization by circulating tumour cells. Nature 529(7586):298\u2013306","journal-title":"Nature"},{"key":"6315_CR18","doi-asserted-by":"crossref","unstructured":"Mitchell J, Lo KW (2023) The Use of Small-Molecule Compounds for Cell Adhesion and Migration in Regenerative Medicine. Biomedicines 11(9):2507","DOI":"10.3390\/biomedicines11092507"},{"issue":"2","key":"6315_CR19","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s00018-021-04104-1","volume":"79","author":"A Gorska","year":"2022","unstructured":"Gorska A, Mazur AJ (2022) Integrin-linked kinase (ILK): the known vs. the unknown and perspectives. Cell Mol Life Sci 79(2):100","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"6315_CR20","first-page":"186","volume":"9","author":"H-FH Can-Can Zheng","year":"2019","unstructured":"Can-Can Zheng1* H-FH, Hong P 1 et al (2019) Significance of integrin-linked kinase (ILK) in tumorigenesis and its potential implication as a biomarker and therapeutic target for human cancer. Am J Cancer Res 9(1):186\u2013197","journal-title":"Am J Cancer Res"},{"issue":"1","key":"6315_CR21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nrc1524","volume":"5","author":"G Hannigan","year":"2005","unstructured":"Hannigan G, Troussard AA, Dedhar S (2005) Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat Rev Cancer 5(1):51\u201363","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"6315_CR22","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s40364-024-00633-6","volume":"12","author":"Y Hu","year":"2024","unstructured":"Hu Y et al (2024) Trop2-targeted therapy in breast cancer. Biomark Res 12(1):82","journal-title":"Biomark Res"},{"key":"6315_CR23","doi-asserted-by":"crossref","unstructured":"Qiu S et al (2023) Targeting Trop-2 in cancer: Recent research progress and clinical application. Biochim Biophys Acta Rev Cancer 1878(4):188902","DOI":"10.1016\/j.bbcan.2023.188902"},{"issue":"9","key":"6315_CR24","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.neo.2021.07.002","volume":"23","author":"E Guerra","year":"2021","unstructured":"Guerra E et al (2021) Trop-2 induces ADAM10-mediated cleavage of E-cadherin and drives EMT-less metastasis in colon cancer. Neoplasia 23(9):898\u2013911","journal-title":"Neoplasia"},{"issue":"8","key":"6315_CR25","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00018-022-04445-5","volume":"79","author":"K Huebner","year":"2022","unstructured":"Huebner K et al (2022) ATF2 loss promotes tumor invasion in colorectal cancer cells via upregulation of cancer driver TROP2. Cell Mol Life Sci 79(8):423","journal-title":"Cell Mol Life Sci"},{"issue":"52","key":"6315_CR26","doi-asserted-by":"publisher","first-page":"20882","DOI":"10.1073\/pnas.0811411106","volume":"105","author":"AS Goldstein","year":"2008","unstructured":"Goldstein AS et al (2008) Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics. Proc Natl Acad Sci U S A 105(52):20882\u201320887","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"6315_CR27","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s40265-020-01337-5","volume":"80","author":"YY Syed","year":"2020","unstructured":"Syed YY (2020) Sacituzumab Govitecan: First Approval. Drugs 80(10):1019\u20131025","journal-title":"Drugs"},{"issue":"16","key":"6315_CR28","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A et al (2021) Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med 384(16):1529\u20131541","journal-title":"N Engl J Med"},{"issue":"18","key":"6315_CR29","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1158\/1078-0432.CCR-23-0536","volume":"29","author":"ML Abel","year":"2023","unstructured":"Abel ML et al (2023) Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial. Clin Cancer Res 29(18):3603\u20133611","journal-title":"Clin Cancer Res"},{"key":"6315_CR30","doi-asserted-by":"crossref","unstructured":"Desai Ae (2022) a., Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer. Lung Cancer, 163, 96\u2013106","DOI":"10.1016\/j.lungcan.2021.12.002"},{"issue":"1","key":"6315_CR31","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1186\/s12951-023-02183-9","volume":"21","author":"C Xu","year":"2023","unstructured":"Xu C et al (2023) TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer. J Nanobiotechnol 21(1):410","journal-title":"J Nanobiotechnol"},{"key":"6315_CR32","doi-asserted-by":"crossref","unstructured":"Rosellini M et al (2021) Treating Prostate Cancer by Antibody-Drug Conjugates. Int J Mol Sci 22(4):1551","DOI":"10.3390\/ijms22041551"},{"issue":"10","key":"6315_CR33","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1158\/1078-0432.CCR-10-2939","volume":"17","author":"TM Cardillo","year":"2011","unstructured":"Cardillo TM et al (2011) Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res 17(10):3157\u20133169","journal-title":"Clin Cancer Res"},{"issue":"6","key":"6315_CR34","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","volume":"32","author":"A Bardia","year":"2021","unstructured":"Bardia A, Kio MW, Berlin EA, Vahdat JD, Masters L, Moroose GA, Santin R, Kalinsky AD, Picozzi K, O\u2019Shaughnessy V, Gray J, Komiya JE, Lang T, Chang JM, Starodub JC, Goldenberg A, Sharkey DM, Maliakal RM, Hong P, Wegener Q, Goswami WA, Ocean T (2021) Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial. Ann Oncol 32(6):746\u2013756","journal-title":"Ann Oncol"},{"issue":"1","key":"6315_CR35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41572-020-00216-3","volume":"6","author":"RE Coleman","year":"2020","unstructured":"Coleman RE et al (2020) Bone metastases. Nat Rev Dis Primers 6(1):83","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"6315_CR36","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/BF00690290","volume":"14","author":"SK Akiyama","year":"1995","unstructured":"Akiyama SK, Yamada OK (1995) Fibronectin and integrins in invasion and metastasis. Cancer Metastasis Rev 14(3):173\u2013189","journal-title":"Cancer Metastasis Rev"},{"key":"6315_CR37","doi-asserted-by":"crossref","unstructured":"E R (1984) Fibronectin in cell adhesion and invasion Cancer Metastasis Rev., 1984;3(1):43\u201351","DOI":"10.1007\/BF00047692"},{"key":"6315_CR38","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1146\/annurev.bi.57.070188.002111","volume":"57","author":"E Ruoslahti","year":"1988","unstructured":"Ruoslahti E (1988) Fibronectin and its receptors. Annual Rev Biochem 57:375\u2013413","journal-title":"Annual Rev Biochem"},{"issue":"2","key":"6315_CR39","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1517\/14712598.2012.646985","volume":"12","author":"S Almokadem","year":"2012","unstructured":"Almokadem S, Belani CP (2012) Volociximab in cancer. Expert Opin Biol Ther 12(2):251\u2013257","journal-title":"Expert Opin Biol Ther"},{"key":"6315_CR40","doi-asserted-by":"crossref","unstructured":"Carter A et al (2010) Integrins as target: first phase III trial launches, but questions remain. J Natl Cancer Inst 102(10):675\u201367","DOI":"10.1093\/jnci\/djq186"},{"issue":"2","key":"6315_CR41","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ygyno.2010.12.362","volume":"121","author":"KM Bell-McGuinn","year":"2011","unstructured":"Bell-McGuinn KM et al (2011) A phase II, single-arm study of the anti-alpha5beta1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol Oncol 121(2):273\u2013279","journal-title":"Gynecol Oncol"},{"issue":"1","key":"6315_CR42","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/annonc\/mds281","volume":"24","author":"B Besse","year":"2013","unstructured":"Besse B et al (2013) Phase Ib safety and pharmacokinetic study of volociximab, an anti-alpha5beta1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer. Ann Oncol 24(1):90\u201396","journal-title":"Ann Oncol"},{"issue":"23","key":"6315_CR43","doi-asserted-by":"publisher","first-page":"7924","DOI":"10.1158\/1078-0432.CCR-08-0378","volume":"14","author":"AD Ricart","year":"2008","unstructured":"Ricart AD et al (2008) Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study. Clin Cancer Res 14(23):7924\u20137929","journal-title":"Clin Cancer Res"},{"issue":"7","key":"6315_CR44","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/s41388-020-01603-6","volume":"40","author":"F Pantano","year":"2021","unstructured":"Pantano F et al (2021) Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions. Oncogene 40(7):1284\u20131299","journal-title":"Oncogene"},{"key":"6315_CR45","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.phrs.2015.10.019","volume":"107","author":"J Meldolesi","year":"2016","unstructured":"Meldolesi J (2016) Pharmacology of the cell\/matrix form of adhesion. Pharmacol Res 107:430\u2013436","journal-title":"Pharmacol Res"},{"issue":"28","key":"6315_CR46","doi-asserted-by":"publisher","first-page":"17283","DOI":"10.1074\/jbc.272.28.17283","volume":"272","author":"AP Mould","year":"1997","unstructured":"Mould AP et al (1997) Defining the topology of integrin alpha5beta1-fibronectin interactions using inhibitory anti-alpha5 and anti-beta1 monoclonal antibodies. Evidence that the synergy sequence of fibronectin is recognized by the amino-terminal repeats of the alpha5 subunit. J Biol Chem 272(28):17283\u201317292","journal-title":"J Biol Chem"},{"issue":"2","key":"6315_CR47","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jss.2014.05.084","volume":"191","author":"HC Hsia","year":"2014","unstructured":"Hsia HC, Nair MR, Corbett SA (2014) The fate of internalized alpha5 integrin is regulated by matrix-capable fibronectin. J Surg Res 191(2):268\u2013279","journal-title":"J Surg Res"},{"key":"6315_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biopha.2018.01.038","volume":"99","author":"HY Chen","year":"2018","unstructured":"Chen HY et al (2018) Integrin alpha5beta1 suppresses rBMSCs anoikis and promotes nitric oxide production. Biomed Pharmacother 99:1\u20138","journal-title":"Biomed Pharmacother"},{"issue":"26","key":"6315_CR49","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1038\/onc.2011.26","volume":"30","author":"A Albasri","year":"2011","unstructured":"Albasri A et al (2011) Cten signals through integrin-linked kinase (ILK) and may promote metastasis in colorectal cancer. Oncogene 30(26):2997\u20133002","journal-title":"Oncogene"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-026-06315-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-026-06315-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-026-06315-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:57:26Z","timestamp":1789606646000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-026-06315-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6315"],"URL":"https:\/\/doi.org\/10.1007\/s00018-026-06315-w","relation":{},"ISSN":["1420-9071"],"issn-type":[{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"23 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Institute Research Ethics Committee at the Sixth Affiliated Hospital of Sun Yat-sen University (Approval number: L2023ZSLYEC-045). Written informed consent was obtained from each patient.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors agree to publish this paper.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"336"}}